Frequent alteration of the protein synthesis of enzymes for glucose metabolism in hepatocellular carcinomas by unknown
ORIGINAL ARTICLE—LIVER, PANCREAS, AND BILIARY TRACT
Frequent alteration of the protein synthesis of enzymes for glucose
metabolism in hepatocellular carcinomas
Takayuki Shimizu • Ken-ichi Inoue •
Hiroyuki Hachiya • Norisuke Shibuya •
Mitsugi Shimoda • Keiichi Kubota
Received: 4 April 2013 / Accepted: 24 September 2013 / Published online: 8 November 2013
 The Author(s) 2013. This article is published with open access at Springerlink.com
Abstract
Background Cancer cells show enhanced glycolysis and
inhibition of oxidative phosphorylation, even in the pre-
sence of sufficient oxygen (aerobic glycolysis). Glycolysis
is much less efficient for energy production than oxidative
phosphorylation, and the reason why cancer cells selec-
tively use glycolysis remains unclear.
Methods Biospecimens were collected from 45 hepato-
cellular carcinoma patients. Protein samples were prepared
through subcellular localization or whole-cell lysis. Protein
synthesis was measured by SDS-PAGE and immunoblot-
ting. mRNA transcription was measured using quantitative
RT-PCR. Statistical correlation among immunoblotting
data and clinicolaboratory factors were analyzed using
SPSS.
Results Enzymes for oxidative phosphorylation (SDHA
and SDHB) were frequently decreased (56 and 48 % of
patients, respectively) in hepatocellular carcinomas. The
lowered amount of the SDH protein complex was rarely
accompanied by stabilization of HIF1a and subsequent
activation of the hypoxia response. On the other hand,
protein synthesis of G6PD and TKT, enzymes critical for
pentose phosphate pathway (PPP), was increased (in 45
and 55 % of patients, respectively), while that of ALDOA,
an enzyme for mainstream glycolysis, was eliminated (in
55 % of patients). Alteration of protein synthesis was
correlated with gene expression for G6PD and TKT, but not
for TKTL1, ALDOA, SDHA or SDHB. Augmented tran-
scription and synthesis of PPP enzymes were accompanied
by nuclear accumulation of NRF2.
Conclusion Hepatocellular carcinomas divert glucose
metabolism to the anabolic shunt by activating transcrip-
tion factor NRF2.
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Human cells maintain their homeostasis through energy
production via glucose catabolism. In the presence of
oxygen, most differentiated cells primarily catabolize glu-
cose to carbon dioxide by oxidation of glycolytic pyruvate
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in the mitochondrial tricarboxylic acid (TCA) cycle (oxi-
dative phosphorylation). On the other hand, cancer cells
‘ferment’ glucose into lactate (glycolysis) even when access
to sufficient oxygen is available [1]. This phenomenon is
known as aerobic glycolysis or the Warburg effect [1]. In
terms of ATP production, oxidative phosphorylation is far
more efficient than glycolysis, and it has long remained
unclear why cancer cells selectively use aerobic glycolysis.
It is becoming more evident that actively proliferating
cells consume glucose not only for ATP production, but
also for the synthesis of nucleotides or fatty acids [2–4].
Cancer cells have a strong demand for replicating all of
their components, and meet those needs by exploiting a
specific branch of glycolysis [5]. The pentose phosphate
pathway (PPP) is a glycolysis shunt that produces the
ribose and nicotinamide adenine dinucleotide phosphate
required for the synthesis of macromolecules [5, 6].
Hepatocellular carcinoma (HCC) is a typical hypervas-
cular tumor and appears to have good access to oxygen [7].
However, the significance of aerobic glycolysis in HCC
remains unclear. Fludeoxyglucose-positron emission
tomography (FDG-PET) is a diagnostic imaging that
exploits the excess glucose uptake by carcinoma cells over
normal (differentiated) cells. While some studies have
reported that FDG-PET is inferior to X-ray computed
tomography in terms of accuracy [8], others have indicated
that FDG-PET is indeed useful for prognostication [9].
Molecular analyses of HCC glycolysis have been performed
using both microarray [10] and immunohistochemistry [11,
12] techniques. Accumulating evidence suggests a possible
causal role of aerobic glycolysis in HCC malignancy.
In the present study, we investigated the enzymes
involved in glucose catabolism in HCC specimens. The
synthesis of each enzyme protein was frequently altered,
and such alteration was mostly consistent with the Warburg
effect, that is, SDHA and SDHB were reduced and syn-
thesis of PPP enzymes was augmented. Unexpectedly,
ALDOA, an enzyme involved in mainstream glycolysis,
was eliminated. The decrease of mitochondrial enzymes
was not accompanied by HIF-1a activation, but augmented
synthesis of PPP enzymes and loss of ALDOA were
accompanied by nuclear accumulation of NRF2. Our
findings confirm that HCC utilizes ‘metabolic reprogram-
ming’ as a fundamental strategy for tumor growth by
activating oncogenic signaling.
Methods
This study had the approval of the Institutional Review
Board (provided ID number: 24089) on the basis of the Ethical
Guidelines for Clinical Research of the Ministry of Health,
Labour and Welfare in Japan (http://www.mhlw.go.jp/
seisakunitsuite/bunya/hokabunya/kenkyujigyou/i-kenkyu/
index.html).
Moreover, this study is registered with the UMIN
Clinical Trials Registry (provided ID number:
UMIN000011465).
Patients and tumor specimens
Biospecimens were collected from patients newly diag-
nosed as having HCC that were undergoing surgical
resection at Dokkyo Medical University Hospital. None of
the patients had received prior treatment for their disease,
including chemotherapy or radiotherapy. All cases were
collected regardless of histologic grade, but those showing
predominance of necrotic and inflammatory cells were
excluded. Each tumor specimen had accompanying non-
tumor tissue, which was cirrhosis in most cases. After
pathological diagnosis, specimens from 45 patients were
used for the present analysis, which was conducted under
strict adherence to ethical guidelines.
Preparation of protein samples
Protein samples were prepared either through subcellular
fractionation or whole-cell lysis. To separate subcellular
localized proteins, we used an NE-PER Nuclear Protein
Extraction Kit (Thermo Scientific, Rockford, IL). Tissue
specimens were weighed and minced with surgical scis-
sors, and the minced tissue was immersed in hypotonic
solution and homogenized in a Dounce homogenizer. After
cell swelling/bursting and brief centrifugation, cytoplasmic
(mitochondrial as well) and nuclear fractions were sepa-
rated. Nuclear proteins were solubilized in RIPA buffer
(25 mM Tris/HCl pH 7.5, 150 mM NaCl, 1 % NP-40, 1 %
sodium deoxycholate), and genomic DNA was fragmented
by sonication (Bioruptor, Diagenode, Liege, Belgium).
Proteins were denatured in lithium dodecyl sulfate (Nu-
PAGE Sample Buffer, Life Technologies, Carlsbad, CA,
USA) and reduced in 50 mM dithiothreitol. Starting with
various specimen weights, and adding various amounts of
reagents, the protein concentrations were adjusted to
around 10 mg/ml (cytoplasm/mitochondria) or 5 mg/ml
(nucleus). Successful fractionation was confirmed by
immunoblotting for GAPDH (cytoplasm) or Histone H3
(nucleus). Alternatively, minced specimens were directly
disrupted by sonication (Bioruptor) in denaturation buffer
(7 M urea, 2 M thiourea, 2 % Triton X-100) and insoluble
debris was removed by centrifugation.
SDS PAGE and immunoblotting
Proteins were size-fractionated by electrophoresis in 8 or
12 % sodium dodecyl sulfate polyacrylamide gel, then wet-
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transferred to a PVDF membrane (Immobilon-P, Merck
Millipore, Billerica, MA, USA). After blocking with 2 %
skim milk or 5 % bovine serum albumin TBST (Tris/HCl
pH 7.4, 150 mM NaCl, 0.1 % Tween20), the membranes
were incubated with each respective primary antibody at
4 C overnight. Non-specific binding was washed away
with TBST and the protein-antibody complex was visual-
ized using horseradish peroxidase-conjugated secondary
antibody (#7074 or 7076, Cell Signaling Technology,
Beverly, MA, USA) and the luminescence reaction (ECL,
ECL prime or ECL select, GE Healthcare, Little Chalfont,
United Kingdom). Images were taken with a CCD camera
and stored in the machine (LAS500, GE Healthcare).
Primary antibodies
For the information about primary antibodies used in
Western blotting, see the Supplemental Table 1.
Reverse transcription-polymerase chain reaction
Total RNA was purified from biospecimens using the gua-
nidine isothiocyanate method (Isogen Plus, Takara Bio Inc.,
Shiga, Japan). mRNA was subsequently reverse-transcribed
to cDNA (Prime Script-RT, Takara Bio Inc.) and the amount
of each mRNA was measured with a real-time PCR machine
(ABI PRISM7000 realtime PCR system, Applied Biosys-
tems, Foster City, CA). The TaqMan probes used are as
follows: Eukaryotic 18S rRNA (#4333760F, Life Technol-
ogies), ALDOA (#Hs00605108_g1, Applied Biosystems),
G6PD (#Hs00166169_m1, Applied Biosystems), TKT
(#Hs01115545_m1, Applied Biosystems), SDHB
(#Hs01042482-m1, Applied Biosystems) and TKTL1
(#Hs00202061_m1, Applied Biosystems). For SDHA
amplification and detection, we utilized web-based qPCR
design software (Universal Probe Assay Design Center,
Roche Applied Science, Penzberg, Germany, https://qpcr.
probefinder.com/organism.jsp). Universal probe #70 was
used for SDHA specific detection and the primer sequences
of upper and lower primers are as follows: Forward 50-
TCCACTACATGACGGAGCAG-30 and Reverse 50-
CCATCTTCAGTTCTGCTAAACG-30. Size of SDHA
product was 82 bp.
Data quantification and statistical analysis
Data from Western blotting was quantified with IQTL
software (version8.1, GE healthcare). We calculated the
relative abundance of protein as the ratio of tumor to non-
tumor band intensity but the data of extremely low amounts
were defined as ‘under detection’. Some molecules were
synthesized exclusively in tumor tissue (e.g., PKM2 or
G6PD) and the data were presented as ‘-’, ‘?’, ‘??’ or
‘???’. The calculated ratio was subsequently normalized
using GAPDH as a standard (ratio of target protein)/(ratio
of GAPDH). Although we initially tested the feasibility of
using GAPDH or b-actin as a standard molecule, GAPDH
found to be superior (see Supplemental Table 2 for the
standard deviation of each ratio). For nuclear proteins,
Histone H3 served as a standard. Data from real-time
RT-PCR was quantified using the 2-DDCt method [13].
Dependencies between groups were analyzed using the chi-
squared test, dividing each variable into two groups (e.g.,
PKM2 synthesized or not). Statistical analyses were per-
formed using the SPSS statistical software package, ver-
sion 20.0 (SPSS Inc., Chicago, IL, USA. Differences at
P \ 0.05 were considered to be statistically significant.
Results
Inhibition of oxidative phosphorylation in HCC
First, we compared the synthesis of subunits of succinate
dehydrogenase (SDH) complex that are functional in the
TCA cycle. In comparison with their non-tumor tissue
counterparts, synthesis of SDHA and SDHB proteins was
reduced in the HCC tumor specimens (Fig. 1). Twenty-
two (among 39 examined, 56 %) and 19 (among 40,
48 %) patients exhibited more than 40 % decrease for
SDHA and SDHB, respectively. These data suggested that
SDH activity was repressed and that the TCA cycle was
arrested. To examine whether the decrease of SDH pro-
teins was due to non-specific protein degradation, we
checked isocitrate dehydrogenase (IDH), another enzyme
involved in oxidative phosphorylation. IDH1 and IDH2
are localized to the cytoplasm and mitochondria, respec-
tively, and we compared the synthesis of each protein
between HCC and each respective non-tumor counterpart
tissue sample. Although some patients exhibited
decreased synthesis of IDH1 (11/37 = 30 %) and IDH2
(12/38 = 32 %), the frequency was not as remarkable as
that observed for SDHA and SDHB.
Pentose phosphate pathway is activated but mainstream
glycolysis is inhibited in HCC
Next we examined the synthesis of the enzyme proteins
glucose-6-phosphate dehydrogenase (G6PD) and transke-
tolase (TKT) in HCC. G6PD and TKT are critical enzymes
in the glycolysis shunt, the pentose phosphate pathway. We
also examined the synthesis of glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) and aldolase (ALDOA), which
are enzymes involved in mainstream glycolysis and
therefore we expected them to serve as internal controls.
Remarkably, synthesis of both G6PD and TKT was
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increased in HCCs relative to the non-tumor counterpart
tissues (Fig. 2). Thirteen (among 29 examined, 45 %) and
21 (among 38, 55 %) patients exhibited this phenomenon
for G6PD and TKT, respectively. On the other hand, syn-
thesis of ALDOA was nearly eliminated (Fig. 2). The ratio
of patients who had lost ALDOA relative to the total
number of patients examined was 55 % (16/29). In con-
trast, synthesis of GAPDH was almost identical in tumor
and non-tumor tissues (Fig. 2) in all of the patients
examined (tumor/non-tumor: mean = 0.96, standard devi-
ation = 0.27, n = 41).
The hypoxia-inducible factor HIF-1a is not activated
in HCCs
Next, we examined the synthesis and accumulation of
HIF-1a protein in nuclear extracts from HCCs. However,
we failed to detect the HIF-1a protein in most of the HCC
patients (2/29 positive, data not shown). As a positive
control, HIF-1a protein was easily detected in the lysate
of Huh7 cells that had been incubated in a hypoxic
chamber (O2 1 %, 4 h, data not shown). Surgically
resected specimens were exposed to ambient oxygen
before preservation in a freezer, and the proteins were
subsequently purified. To exclude the possibility that HIF-
1a protein would have been degraded during sample
preparation, we checked the events downstream of HIF-
1a activation. When we compared the protein synthesis of
cytochrome oxidase IV (COX4-1), a negative target of
HIF-1a, 18 % of the patients (7/39) displayed a reduced
level of COX4-1 protein (Fig. 3). We also examined the
synthesis of PKM2 and LDHA, positive targets of HIF-
1a. However, synthesis of the PKM2 protein was
observed in 15 % (6/41) of the HCC patients (Fig. 3) and
for LDHA, only 8 % of the patients (3/39) displayed
augmented protein synthesis (Fig. 3).
Frequent nuclear accumulation of NRF2 protein
in HCCs
Next, we examined the nuclear localization of a tran-
scription factor NRF2. In contrast to HIF-1a, which was
hardly detectable by the same method, NRF2 protein was
detected in tumor tissue and occasionally in non-tumor
tissue (Fig. 4). We used two different monoclonal anti-
bodies recognizing distinct epitopes, but the data mostly
overlapped (Fig. 4). The ratio of patients who possessed
nuclear NRF2 relative to the total examined was 22/30 (73
% for NRF2 C-terminal) and 22/30 (77 % for phosphory-
lated S40 of NRF2). However, synthesis of KEAP1, an E3
uniquitin ligase against NRF2, varied (increase: 7/24,
decrease: 9/24, unchanged: 8/24, data not shown).
Fig. 1 Frequent reduction of SDHA and SDHB synthesis in HCCs.
Fifty lg of protein of whole-tissue lysate were loaded in each well,
and Western blotting for TCA cycle enzymes was performed. Tumor/
non-tumor paired samples were placed side by side. The band
intensity was quantified with densitometry and the ratio between
tumor/non-tumor were presented. GAPDH serves as an internal
control. Eight representative specimens are shown
Fig. 2 Frequently increased synthesis of G6PD and TKT, and loss of
ALDOA synthesis, in HCCs. Fractionated cytoplasmic/mitochondrial
proteins were loaded in each well and Western blotting for glycolysis/
PPP enzymes was performed. Tumor/non-tumor paired samples were
placed side by side. The band intensity was quantified with
densitometry and the ratio between tumor/non-tumor was presented.
b-actin serves as a loading control. Five representative specimens are
shown
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Augmented synthesis of PPP proteins were correlated
with mRNA induction
Next, we measured mRNA transcription of genes that
encode G6PD, TKT, ALDOA, SDHA or SDHB protein. As
expected, gene transcription of G6PD was increased and
correlated well with protein synthesis (Supplementary
Fig. 1). The TKT protein is encoded by three distinct
genes, TKT, TKTL1 or TKTL2. Although TKTL1 mRNA is
known to be induced in some tumors (for review, see
Riganti et al. [14]), only trace amounts of the TKTL1
mRNA were expressed, and we determined that the data
were out of quantification range (data not shown). How-
ever, the TKT gene was abundantly expressed and further
increased in tumor tissue (Supplementary Fig. 2), indicat-
ing that G6PD and TKT could be upregulated by a tran-
scription factor, NRF2. On the other hand, transcription of
the ALDOA gene was poorly correlated with protein syn-
thesis (Supplementary Fig. 3). Fifty-eight percent of
patients (7/12) displayed increased ALDOA expression,
although most of these patients displayed loss of ALDOA
protein (Supplementary Fig. 3). Thus, transcription of the
ALDOA gene and the synthesis of ALDOA protein dis-
played an inverse relationship. We also examined the
SDHA and SDHB gene transcription. However, neither
SDHA (Supplementary Fig. 4) nor SDHB (Supplementary
Fig. 5) had any apparent relationship between mRNA
transcription and protein synthesis. Fifty percent (6/12) and
67 % (8/12) of patients displayed an inverse relationship
with SDHA and SDHB, respectively.
SDH reduction did not correlate with hypoxia response,
while increased synthesis of PPP enzymes correlated
with activation of NRF2
Finally, statistical analysis was performed to examine the
dependencies among HIF-1a activation, and alteration of
LDHA, PKM2, SDHA, SDHB and COX4-1 (Table 1).
HIF-1a activation was significantly correlated with PKM2
synthesis (P = 0.02). Synthesis of PKM2 was inversely
correlated with decreased synthesis of SDHB
(P = 0.033*). Decreased COX4-1 synthesis was signifi-
cantly correlated with decreased synthesis of SDHA and
SDHB (P = 0.009 and P = 0.001, respectively), and
decreased SDHA synthesis was significantly correlated
with decreased SDHB synthesis (P \ 0.001).
Fig. 3 Occasional degradation of COX4-1, synthesis of PKM2 and
augmented LDHA synthesis in HCCs. Fifty lg of protein of whole-
tissue lysate were loaded in each well, and Western blotting for HIF-1
targets/modulators was performed. Tumor/non-tumor paired samples
were placed side by side. The band intensity was quantified with
densitometry and the ratio between tumor/non-tumor were presented.
GAPDH serves as an internal control. Eight representative specimens
are shown
Fig. 4 Frequent accumulation of NRF2 proteins in HCC nuclei.
Fractionated nuclear proteins were loaded in each well, and Western
blotting for NRF2 was performed. Tumor/non-tumor paired samples
were placed side by side. The band intensity was quantified with
densitometry and the ratio between tumor/non-tumor was presented.
Histone H3 serves as an internal control. Five representative
specimens are shown
Table 1 Dependencies between HIF-1a activation and alteration of
glycolytic enzyme




SDHA 0.747 0.920 0.067
SDHB 0.727 0.234 0.033* <0.001
COX4-1 0.197 0.971 0.944 0.009 0.001
Asterisk denotes inverse correlation
Bold number denotes statistically significant
Chi-square test, P \ 0.05
HIF1a Hypoxia-induced factor 1a, LDHA Lactate dehydrogenase,
PKM2 Pyruvate kinase M2, SDH Succinate dehydrogenase
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We next analyzed the dependencies between NRF2
activation (nuclear NRF2) and other protein alterations
(Fig. 5). NRF2 activation was significantly correlated with
G6PD synthesis (P = 0.044, Table 2) and with TKT
(P = 0.04, Table 2), but not with other variables (data not
shown).
Statistical analysis was also performed to compare the
Western blotting data with various clinicolaboratory fac-
tors, such as tumor differentiation, number of tumors,
tumor size, UICC TNM staging (7th edition), tumor
markers (AFP, PIVKA-II), AST, ALT, Alb, CRP, PLT, and
hepatitis viral infection (all the information are presented in
Supplementary Table 2). Increased expression of G6PD
was significantly correlated with moderate or poor differ-
entiation (P = 0.007). Augmented NRF2 activation was
significantly correlated with invasive growth (P = 0.041).
PIVKA-2 was significantly correlated with NRF2 activa-
tion and an increase of TKT (P = 0.004, P = 0.014). AFP
was significantly correlated with an increase of G6PD and
a decrease of IDH1 (P = 0.018, P = 0.015). ICGR15 was
significantly correlated with IDH1 decrease (P = 0.008).
Hepatitis virus C infection was significantly correlated with
ALDOA decrease (P = 0.036, patients who had HCV vs.
those who had HBV).
Discussion
In this study, we collected specimens of HCC from Japa-
nese patients and examined the synthesis of enzymes
involved in glucose metabolism. In comparison to other
solid tumors, the tissue composition of HCC is relatively
uniform in both the tumor and non-tumor components.
Data obtained from subcellular fractionation and Western
blotting could reflect the metabolic status of HCC in situ.
Our present findings are mostly consistent with Warburg’s
original report, although we discovered some unexpected
phenomena as well.
Overall, the liver is a hypervascular organ, and thus
HCC is likely to have a good oxygen supply during tumor
formation. Nevertheless, HCC intensively induces angio-
genesis and grows into an apparently vascular-rich tumor.
One possible explanation is that HIF-1 is activated under
normoxic conditions and induces vascular endothelial
growth factor. We observed that synthesis of SDHA and
SDHB was frequently reduced (22/39 and 19/40, respec-
tively) in HCCs (Fig. 1). SDHB is a tumor suppressor of
familial paraganglioma or pheochromocytoma [15, 16],
and loss of its function leads to succinate accumulation
[17]. Succinate is a substrate of SDH and its accumulation
Fig. 5 Relationships between
NRF2 activation and G6PD or
TKT increase. Upper Scatter
plot of relative abundance of
protein shows nuclear NRF2 (y-
axis) and glycolysis enzymes (x-
axis). Quantitative data are
presented in log-scale
(base = 2). Lower For patients
who displayed undetectable
NRF2 protein, protein levels of
enzymes are shown as one-
variable plots. P value is
calculated with the chi-square
test











Not activated 7 6 0.044
TKT
Activated 14 2
Not activated 7 6 0.04
Chi-squared test
G6PD Glucose-6-phosphate dehydrogenase, TKT transketalase
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results in inhibition of prolyl hydroxylase and subsequent
stabilization of HIF-1a [17]. Activation of HIF-1a, in turn,
induces LONP1, a protease that degrades mitochondrial
protein cytochrome oxidase IV (COX4-1) and inhibits
oxidative phosphorylation [18]. Moreover, HIF-1a activa-
tion enhances LDHA gene expression [3], and the cooper-
ative activation of HIF-1a and PKM2 is the driving force
of aerobic glycolysis [19]. Thus, SDH function and HIF-1
are closely related to each other, and we had expected that
SDHA/SDHB reduction would be accompanied by HIF-1
activation. However, we concluded that this was not the
case, based on certain items of evidence. First, HIF-1a
protein was detected in only 7 % of HCC patients (2/29).
Second, augmented synthesis of a transcription target
(LDHA) was also a rare event in HCCs (8 % = 3/39).
Third, although activation of PKM2 was occasional
(15 % = 6/41), it was inversely correlated with SDHA/
SDHB reduction (Table 1). Indeed, statistical analysis
indicated that alteration of COX4-1 was correlated with
SDHA/SDHB decrease (Table 1), and this specific variable
could partly explain the decrease of SDH (mitochondrial
remodeling). Other variables (HIF-1a, PKM2 and LDHA),
however, were not positively correlated with SDHA/SDHB
decrease. It is generally accepted that hypoxia-inducible
factors play crucial roles in hepatocellular carcinogenesis
[20]. Previous studies used immunohistochemistry to
detect HIF-1a in HCC specimens [21–23]. We cannot
exclude the possibility that HIF-1a was activated below the
detection range of our present method, or that other HIF
proteins were activated instead [24]. However, we specu-
late that activation of HIF-1a is not a predominant factor of
HCCs in Japanese patients.
The accumulation of NRF2 in HCC nuclei (73 % = 22/30
for NRF2 C-terminal and 77 % = 23/30 for phosphory-
lated S40 of NRF2) was another major discovery. Recently,
comprehensive exome sequencing of HCC has been carried
out, and frequently mutated genes have been reported [25].
Among four newly identified genes, NFE2L2 encodes
NRF2 protein [25]. NRF2 was originally identified as a
transcription factor that responds to various stress signals,
such as oxidative stress [26]. Upon activation by such
stresses, NRF2 induces a series of detoxifying enzymes and
antioxidant genes [26]. Under normal conditions, E3
ubiquitin ligase KEAP1 maintains NRF2 at a very low
level through the ubiquitin–proteasome degradation system
[27, 28]. In addition to the well-known target genes of
NRF2, Motohashi and colleagues have identified PPP
enzymes (G6PD, PGD, TKT and TALDO1) as novel tar-
gets of NRF2 [29]. Our findings are consistent with their
report: NRF2 translocation to nuclei involved an increase
of G6PD and TKT (Figs. 2, 4). Interestingly, their study
verified that oncogenic PI3 kinase signaling augments Nrf2
translocation to murine hepatocyte nuclei [29]. We also
observed occasional NRF2 accumulation in nuclei of non-
tumor cirrhotic tissue, but the amount was mostly higher in
tumor tissue (77 % = 17/22 for NRF2 C-terminal or
70 % = 16/23 for phosphorylated S40 of NRF2). These
data suggest that the oncogenic signal is needed to augment
NRF2 translocation in HCCs.
Constitutive stabilization/activation of NRF2 protein is a
prognostic indicator in some cancers [30–32]. Several
different mechanisms can explain NRF2 activation: (1)
point mutation in the KEAP1 or NFE2L2 gene [30, 31, 33,
34]; (2) synthesis of an inhibitor of KEAP1-NRF2 inter-
action [35–37]; (3) promoter methylation and silencing of
the KEAP1 gene [38, 39]; (4) succination of KEAP1 and
subsequent dissociation of KEAP1-NRF2 interaction [40].
Two studies have reported that the rate of point mutation in
the NFE2L2 gene is 6.4 % [25] and in the KEAP1 gene is
8.9 % [41]. Although we did not carry out mutational
screening in this series of Japanese HCC cases, the modest
frequency of point mutation is unlikely to explain the high
incidence of nuclear translocation of NRF2 (Supplemen-
tary Table 2). Alternatively, chronic inflammation results
in deregulation of autophagy, leading to accumulation of
an inhibitor of KEAP1-NRF2 interaction [36, 42]. The
possibility that increased succinate caused by loss
of SDHA/SDHB might result in KEAP1 succination is also
intriguing [40].
Unexpectedly, we observed that ALDOA protein was
frequently eliminated in HCCs (Fig. 2). Three isozymes
are encoded by three different genes: ALDOA, ALDOB and
ALDOC. It has been reported that the expression of ALD-
OB mRNA is reduced in HCCs [43], whereas that of
ALDOA mRNA is increased [44], thus fitting the conven-
tional concept of enhanced glycolysis. Indeed, as for
mRNA expression, we confirmed that this was the case in
Japanese HCC specimens (Supplementary Fig. 3). Never-
theless, the synthesis of ALDOA protein did not correlate
with mRNA expression (Supplementary Fig. 3). Of note,
the band of ALDOA was migrated more slowly in tumor
specimens compared to non-tumor counterparts (Fig. 2). It
is possible that ALDOA protein is constantly degraded due
to post-translational modification, such as ubiquitination.
Aldolase catalyses a reversible aldol reaction utilizing not
only fructose 1,6-bisphosphate, but also sedoheptulose 1,7-
bisphosphate as substrates. The latter is located in the non-
oxidative arm of PPP and this specific branch is known to
be regulated by oncogenic signaling [45]. Future studies
will need to clarify whether ALDOA is simply a bystander
or an active driver of carcinogenesis.
There are a couple of differences between the classical
definition of the Warburg effect and our present obser-
vations (Supplementary Fig. 6). First, increased expression
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of LDHA (an enzyme for lactate production) was a rare
event (8 % = 3/39). Second, synthesis of PKM2 (a driver
of aerobic glycolysis) was occasional (15 % = 6/41), but
inversely correlated with a reduction of SDH proteins.
Third, ALDOA (an enzyme for mainstream glycolysis)
was frequently eliminated (55 % = 16/29). Currently, we
are extending our analysis to other gastrointestinal tumors
such as colorectal carcinomas (CRCs). In contrast to
HCCs, CRCs frequently synthesized PKM2 protein and
increased ALDOA protein (Supplementary Fig. 6, N.
Shibuya, K. Inoue and K. Kubota, manuscript in prepa-
ration). Increased PPP enzymes, however, were observed
in CRCs as well (Supplementary Fig. 6). Data indicate
that the Warburg effect, at least in HCC, does not fit the
stereotypic form originally proposed. If HCC does not
augment mainstream glycolysis, the net glusose uptake of
tumor cells could be similar to those of surrounding
hepatocytes. Although further evidence is needed, this
could be the reason why the usefulness of FDG-PET is
relatively low compared to other tumors (difficult to dis-
tinguish the change of FDG uptake).
Lastly, but not least, metabolic reprogramming seems to
be a fundamental survival strategy of cancer cells [46]. In
the near future, a more comprehensive understanding of
aerobic glycolysis may lead to the design of novel thera-
peutic strategies for HCC.
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